Circulating biomarkers in leukemia
Clinica Chimica Acta · 2026-03 · 584 · 120865
DOI: 10.1016/j.cca.2026.120865 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2026-03. Verfasst von Aiyun Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province 030001, China. Electronic address: 13834541328@16…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Leukemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 178 Literaturangaben.
Abstract (Originalsprache)
Liquid biopsy is a minimally invasive approach that analyzes circulating biomarkers, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), microRNAs (miRNAs), and extracellular vesicles (EVs), to provide real-time information about the genetic and epigenetic state of hematologic malignancies. Compared with bone-marrow biopsy, blood-based assays enable serial sampling and can better capture temporal changes and spatial heterogeneity. Advances in high-throughput sequencing and digital PCR have improved detection sensitivity for minimal residual disease (MRD), clonal evolution, and resistance mutations. Integration of circulating biomarkers into clinical care may support personalized treatment decisions and earlier relapse detection, but barriers remain: assay standardization, biological variability, and interpretation of low-frequency variants. Interpretation of existing clinical studies suggests that ctDNA kinetics (for example, early on-treatment clearance vs persistent detection) frequently correlate with progression-free and overall survival (OS) in lymphoid and myeloid malignancies, supporting ctDNA as a candidate early surrogate of treatment benefit; however, sensitivity differs by disease biology (marrow-predominant AML vs nodal lymphomas) and therefore ctDNA should be used in combination with marrow-based MRD and leukocyte sequencing until prospective standardization is established. This review summarizes current technologies, clinical applications, and translational opportunities for circulating biomarkers in leukemia and discusses outstanding challenges for clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province 030001, China. Electronic address: 13834541328@163.com.
- Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Alborz University of Medical Sciences, Karaj, Iran.
- Department Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
- High Institute for Education and Research in Transfusion Medicine:Tehran, Iran.
- Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Zitieren
APA
Dong, A., Jahedi Zargar, M., Mirzazadeh, A., Khaksari, M. N., Nazari, M., Pilehvari, N., & Soleimani Samarkhazan, H. (2026). Circulating biomarkers in leukemia. Clinica Chimica Acta, 584, 120865. https://doi.org/10.1016/j.cca.2026.120865
Vancouver
Dong A, Jahedi Zargar M, Mirzazadeh A, Khaksari MN, Nazari M, Pilehvari N, et al. Circulating biomarkers in leukemia. Clinica Chimica Acta. 2026;584:120865. doi:10.1016/j.cca.2026.120865
BibTeX
@article{Dong2026,
author = {Dong, Aiyun and Jahedi Zargar, Mehdi and Mirzazadeh, Amirhossein and Khaksari, Mohammad Navid and Nazari, Mobina and Pilehvari, Niloofar and Soleimani Samarkhazan, Hamed},
title = {Circulating biomarkers in leukemia},
journal = {Clinica Chimica Acta},
year = {2026},
volume = {584},
pages = {120865},
doi = {10.1016/j.cca.2026.120865}
}
EUVIMED